Author:
Dohrn Maike F.,Lampert Angelika,Üçeyler Nurcan,Kurth Ingo
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21
2. Alexandrou AJ, Brown AR, Chapman ML et al (2016) Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release. PLoS ONE 11:e152405
3. Attal N, Cruccu G, Baron R et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17:1113–e1188
4. Baron R, Birklein F, Maier C, Quasthoff S, Sommer C, Tölle T et al (2016) Leitlinie „Therapie neuropathischer Schmerzen“ der Deutschen Gesellschaft für Neurologie (DGN)
5. Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22–31
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献